Pieper Steven sold $47K of XERS
Pieper Steven (See Remarks) sold 5,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $9.41 on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is unlikely to affect Xeris' share price materially.
Market read
Minor insider sell; limited relevance for traders.
What to watch
The sale was pre‑arranged under a 10b5‑1 plan, indicating no new information drove the transaction.
Background
Form 4 filings provide transparency on insider transactions. Small sales under a 10b5‑1 plan are routine and often have little market impact.
Ticker impact
SEC Form 4 disclosed that officer Steven Pieper sold 5,000 shares of Xeris Biopharma for $47,036.50 on Oct 1 via a 10b5‑1 plan.
likely minimal pressure as the market absorbs a small insider sell.
The transaction amount is under $50k and represents a tiny fraction of total holdings, so traders should not expect a material price reaction.
Market effects
None significant; the sale does not affect the broader biotech sector.
No regional impact.
Limited to Xeris shareholders.
Counterpoint
Some investors may view any insider sell as a negative signal, but the size is too small to warrant a contrarian trade.
Key entities
- OfficerSteven Pieper
Officer of Xeris Biopharma who sold shares under a 10b5‑1 plan.
